A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials ; volume:9 ; number:1 ; day:14 ; month:9 ; year:2011 ; pages:1 ; date:12.2011
Pediatric rheumatology ; 9, Heft 1 (14.9.2011), 1, 12.2011
- Creator
-
Demirkaya, E.
Ruperto, N.
Galasso, R.
Ravelli, A.
Palmisani, E.
Martini, A.
Pistorio, A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1546-0096-9-S1-P192
- URN
-
urn:nbn:de:101:1-2019091820274325332312
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Demirkaya, E.
- Ruperto, N.
- Galasso, R.
- Ravelli, A.
- Palmisani, E.
- Martini, A.
- Pistorio, A.
- SpringerLink (Online service)
Other Objects (12)
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Quality improvement in juvenile idiopathic arthritis: a mixed-methods implementation pilot of the CAPTURE-JIA dataset
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Quality improvement in juvenile idiopathic arthritis: a mixed-methods implementation pilot of the CAPTURE-JIA dataset
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)